TB-500 is not thymosin beta-4
Last updated: October 27, 2026 · 5 min read · By the Grey Peptides Editorial Board
- Thymosin beta-4 is a 43-amino-acid protein that holds actin in reserve inside cells. The TB-500 identified in a product analysed by a doping-control laboratory was a seven-amino-acid piece of it, acetylated: Ac-LKKTETQ.
- The human studies in this article all used full-length thymosin beta-4: an intravenous safety study, a venous-ulcer study, and eye-drop trials for dry eye and corneal healing. None of it tested the fragment.
- A label reading TB-500 does not say which molecule is in the vial; the name is used for both. WADA's 2026 List bans them together under S2.3, as thymosin beta-4 and its derivatives.
Two molecules, one name
Thymosin beta-4 Medium is 43 amino acids long, and biochemistry from 1993 showed it is primarily an actin monomer sequestering protein: it holds single actin molecules in reserve and slows their assembly into filaments 1. Here is its full sequence, with the seven residues at positions 17 to 23 marked:
SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES
TB-500 Low is the name on vials sold online. When the Ghent doping-control laboratory analysed TB-500, it identified the N-terminally acetylated fragment Ac-LKKTETQ, residues 17 to 23 2. The Hong Kong Jockey Club's laboratory, writing about the veterinary preparation for horse racing, described its key ingredient as LKKTETQ with an artificial acetyl group, the segment of thymosin beta-4 it calls responsible for actin binding, cell migration and wound healing 3. A 2024 doping-control study notes those functions were shown for the unacetylated form, and that the biological effects of TB-500 itself had not been documented 4.
Whose evidence is it?
The human studies belong to the full protein. A randomised, placebo-controlled study gave healthy volunteers single and then 14 daily intravenous doses of synthetic thymosin beta-4 at 42, 140, 420 or 1,260 mg, with infrequent adverse events, mild or moderate in intensity 5. A double-blind, placebo-controlled dose-escalation trial in Italy and Poland set out to test it topically on venous leg ulcers; the 2007 report describes the design and an ongoing enrolment of 21 patients in the first group, with no results 6. The furthest it went was the eye: 0.1% thymosin beta-4 drops, known as RGN-259, reduced discomfort by 35.1% and corneal staining by 59.1% at day 56 in a nine-patient phase 2 study of severe dry eye 7, and in an 18-patient phase 3 trial in neurotrophic keratopathy, 6 of 10 treated subjects and 1 of 8 on placebo had complete healing at four weeks, a difference the authors, some from the developers ReGenTree and HLB Therapeutics, call a strong trend (p = 0.0656) 8. A personal review by the same investigator traces that path from bench to bedside 9.
The fragment's literature is different in kind. The papers that name TB-500 are mostly about detecting it: methods for finding Ac-LKKTETQ and its breakdown products in urine and plasma, tested in horses and rats 2 3 4. The rat work also screened the fragment and its metabolites in fibroblast culture: none was toxic, and only the metabolite Ac-LKKTE, not TB-500 itself, showed significant wound-healing activity 4. We found no published human trial of the fragment.
What the confusion does to the claims
Every human trial above used thymosin beta-4, a molecule six times longer, given intravenously, topically or as eye drops. Three things do not carry over from one to the other. The dose: milligrams of a 43-residue protein are not milligrams of a 7-residue fragment, and no human dose of the fragment has been studied. The behaviour in the body: a short acetylated peptide is broken down and cleared differently, and in the rat study its main metabolite appeared within the first six hours while a longer one stayed detectable for up to 72 hours 4. And the safety record: the intravenous safety data and the eye-drop trials say nothing about a fragment injected under the skin for weeks.
The same caution applies to the cancer question. Reviews of thymosin beta-4 in heart repair note its involvement in tumour biology alongside its repair effects 10; whether the fragment shares that involvement has not been studied either way.
What is actually in the vial
The name does not reliably fix the contents. The question our Name Decoder tells buyers to ask is whether a TB-500 vial holds the short fragment or the full protein, and the two differ hugely in mass: about 889 daltons for Ac-LKKTETQ against about 4,963 for N-acetylated thymosin beta-4 11. A certificate of analysis should state which one and give a mass that matches; the Name Decoder lists the question, and the COA Decoder explains how to check the answer.
For sport the distinction does not matter: WADA's 2026 Prohibited List names "thymosin-β4 and its derivatives e.g. TB-500" under S2.3, growth factors and growth factor modulators 12. For everyone else it decides which evidence, if any, applies to what they are injecting.
Frequently asked questions
Is TB-500 the same as thymosin beta-4?
No. Thymosin beta-4 is a 43-amino-acid protein; the TB-500 identified in a product analysed by a doping-control laboratory was Ac-LKKTETQ, an acetylated seven-amino-acid fragment from positions 17 to 23. A label alone does not say which molecule a vial holds.
Has TB-500 been tested in humans?
Not the fragment, as far as published studies show. The human studies people cite, intravenous safety, venous ulcers and eye drops, all used full-length thymosin beta-4.
What is TB4 frag?
A seller name for a short piece of thymosin beta-4, usually the actin-binding stretch LKKTETQ. The evidence for full-length thymosin beta-4 does not transfer to it automatically.
Is TB-500 banned in sport?
Yes. WADA's 2026 List names thymosin beta-4 and its derivatives, including TB-500, under S2.3.
Related on Grey Peptides
Sources
- Yu, F. X., et al. (1993). Thymosin beta 10 and thymosin beta 4 are both actin monomer sequestering proteins. J Biol Chem, 268(1), 502-9. PMID: 8416954
- Esposito, S., et al. (2012). Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal, 4(9), 733-8. PMID: 22962027 · doi:10.1002/dta.1402
- Ho, E. N., et al. (2012). Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A, 1265, 57-69. PMID: 23084823 · doi:10.1016/j.chroma.2012.09.043
- Rahaman, K. A., et al. (2024). Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS and their screening by wound healing activities in-vitro. J Chromatogr B Analyt Technol Biomed Life Sci, 1235, 124033. PMID: 38382158 · doi:10.1016/j.jchromb.2024.124033
- Ruff, D., et al. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci, 1194, 223-9. PMID: 20536472
- Guarnera, G., et al. (2007). Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study on safety, tolerability, and enhancement on healing. Ann N Y Acad Sci, 1112, 407-12. PMID: 17495250
- Sosne, G., et al. (2015). Thymosin β4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial. Cornea, 34(5), 491-6. PMID: 25826322
- Sosne, G., et al. (2022). 0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial. Int J Mol Sci, 24(1). PMID: 36613994
- Sosne, G. (2018). Thymosin beta 4 and the eye: the journey from bench to bedside. Expert Opin Biol Ther, 18(sup1), 99-104. PMID: 30063853
- Bjørklund, G., et al. (2020). Thymosin β4: A Multi-Faceted Tissue Repair Stimulating Protein in Heart Injury. Curr Med Chem, 27(37), 6294-6305. PMID: 31333080
- Average molecular masses computed from the sequences with standard average residue masses: Ac-LKKTETQ 889.0 Da; N-acetylated thymosin beta-4 (43 residues) 4,963.5 Da. Calculated October 27, 2026.
- World Anti-Doping Agency. Prohibited List 2026, section S2.3 ("Thymosin-ß4 and its derivatives e.g. TB-500"); read October 2, re-read October 27, 2026. WADA
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead